OncoPharm Talazoparib
Oct 18, 2018
Explore the recent FDA approval of talazoparib, a cutting-edge PARP inhibitor for breast cancer patients with BRCA mutations. Delve into its unique mechanism of action and effectiveness in comparison to olaparib. Understand key clinical considerations that doctors and patients should be aware of when choosing treatments. This discussion highlights advancements in cancer therapy and their implications for patient care.
AI Snips
Chapters
Transcript
Episode notes
Talazoparib Mechanism And Approval
- Talazoparib is the fourth FDA-approved PARP inhibitor, approved for germline BRCA-mutated locally advanced or metastatic breast cancer.
- It inhibits PARP1/2 and shows strong PARP trapping, which may drive hematologic toxicity.
Why PARP Inhibitors Work In BRCA Mutations
- PARP repairs single-strand DNA breaks and PARP inhibition converts those to double-strand breaks.
- BRCA-deficient cells cannot repair these double-strand breaks, producing synthetic lethality with PARP inhibitors.
EMBRACA Efficacy Results
- The EMBRACA trial randomized 431 patients 2:1 to talazoparib versus physician-choice chemo and showed a median PFS benefit of 8.6 vs 5.6 months (HR 0.54).
- Overall survival was not significantly different, but response rates and complete responses favored talazoparib.